Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Irritable Mood, Huntington's Disease

In brief

This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.

Key facts

Study ID: NCT02507284
Run by: Azevan Pharmaceuticals
People needed: 106
Starts: 2016-05-10
Expected to finish: 2018-12-21
Last updated by the study team: 2023-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male and female Subjects aged 18 years or older
Subjects must have clinical features of HD, which can include motor, cognitive, or behavioral symptoms
A confirmatory family history of HD; OR CAG repeat expansion ≥ 37
Total Functional Capacity (TFC) score of 5-13
Evidence of irritability; a score of at least 2 or greater on the severity measure of either the UHDRS Irritability question (30b) or Aggression question (Disruptive or Aggressive Behavior, 31b)
Women of childbearing potential (i.e., those not postmenopausal or surgically sterile) must have a negative pregnancy test, be non-lactating and use adequate contraception methods during the study. Adequate birth control includes: abstinence; oral, implanted or injected contraceptives, e.g., birth control pills; intra-uterine device; barrier (vaginal ring or diaphragm/cervical cap with spermicide); transdermal patch. Reliable contraception must have been in use 30 days prior to the Baseline Visit. Partner(s) contraception (e.g., male partner with vasectomy or other surgical contraception) is acceptable.
Men must agree not to father a child during the study and one month after and to use contraception. Barrier with spermicide or surgical contraception is acceptable. Partner(s) contraception (e.g., female partner taking birth control pills or surgically sterile) is acceptable.
Subjects must be able to swallow study drug capsules whole.
Sufficient English skills to complete all assessments without assistance of an English language interpreter. Subjects with HD who cannot read or write might qualify for enrollment in the study. Site PIs will have to decide in each case whether the Subject can understand and fully participate with help from his/her Informant.
Availability of a responsible Informant (referred to as a "study partner" in the consent document) who has good English skills, is familiar with the Subject, and is able and willing to comply with all required study procedures, ensuring that the patient attends all study visits and takes the study medicine as instructed. The study partner must spend time with the patient a minimum of 4 times per week on 4 separate days, and must monitor the patient's compliance and adverse events, participate in caregiver assessments, and use the eDiary.
Subject has provided written, informed consent or, if Subject lacks the capacity to provide informed consent (as determined by an independent assessment by a qualified healthcare provider not directly involved in other study activities), a legally authorized representative (LAR) has provided written informed consent and the Subject has provided assent.

You may not qualify if…

Any significant neurologic disease other than HD at Screening.
Severe psychotic features or other severe psychiatric symptoms within the last three months which could lead to difficulty complying with the protocol.
History of active alcohol or substance abuse within the past two years or Subject is unable to refrain from substance abuse throughout the study.
Any chronic disability, significant systemic illness or unstable medical condition at Screening or Baseline that could lead to difficulty complying with the protocol.
Use of any investigational drugs within 30 days of Screening.
Subject has known allergy to any of the components of study medication.
Subject is currently pregnant, breast-feeding and/or lactating.
Subject acknowledges present use of illicit drugs at Screening.

Where it is running

University of Alabama — Birmingham, Alabama, United States
UCLA, Neurology Clinic — Los Angeles, California, United States
UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center — Sacramento, California, United States
University of Colorado Hospital Translational Research Center — Aurora, Colorado, United States
University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital — Miami, Florida, United States
Emory University — Atlanta, Georgia, United States
Northwestern Out-Patient Neurology Clinic — Chicago, Illinois, United States
University of Kansas Medical Center — Kansas City, Kansas, United States
Massachusetts General Hospital — Charlestown, Massachusetts, United States
Washington University School of Medicine — St Louis, Missouri, United States
SUNY Stony Brook Clinical Research Center, Department of Neurology — East Setauket, New York, United States
Columbia University Medical Center, New York Presbyterian Hospital — New York, New York, United States
University of Rochester Medical Center — Rochester, New York, United States
University Medical Arts Building — Cincinnati, Ohio, United States
Ohio State University, Wexner Medical Center, Department of Neurology — Columbus, Ohio, United States
Oregon Health and Science University — Portland, Oregon, United States
University of Pittsburgh Medical Center, Department of Neurology — Pittsburgh, Pennsylvania, United States
Vanderbilt Clinical Research Center — Nashville, Tennessee, United States
UT Southwestern Medical Center — Dallas, Texas, United States
University of Utah, Department of Neurology — Salt Lake City, Utah, United States
University of Virginia Health System, Department of Neurology — Charlottesville, Virginia, United States
Swedish Neuroscience Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.